FDA Approves Lebrikizumab for Atopic Dermatitis
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of
Lancashire loanee Simon Kerrigan struck a career-best 62 and Rob Newton pronounced himself king of the half-centuries as Northants achieved
The Mexican Peso (MXN) trades lower on Tuesday extending the downtrend of the last few days as political risk weighs. Investors
No posts found.